Abstract
Auranofin (AF), an orally administered antirheumatic drug, reduces the ATP level of PMN cells in vitro in a dose-dependent manner and provokes various effects on PMN migration. Under the experimental conditions, AF in concentrations between 10−8 M and 10−3 M produced a statistically significant (P < 0.05) dose-related reduction in ATP level, which ranged from 89% of the control value with 10−8 M AF to 46.8% of the control with 10−3 M AF. On the other hand, the combination of AF and the chemoattractant LTB4 (1 ng/ml) shows agonistic effects on the intracellular ATP level. AF at 10−5 M significantly increases the ATP (33%;P < 0.03). In general migration of PMN cells is stimulated by 10−7 M AF [chemotactic index (CI)=1.26], but inhibited by 10−5 M (CI=0.65), 10−4 M (CI=0.09) and 10−3 M AF (CI=0.01). These effects were statistically significant atP < 0.05. In the presence of LTB4 (1 ng/ml), which resulted in an average CI of 2.9, AF also inhibits the chemotactic effect of the chemoattractant, with the CI being significantly reduced at 10−6 M AF (CI=2.3) and 10−4 M AF (CI=0.05). In the latter case the effect was also confirmed by the leading-front technique. AF at 10−6 M is a level that could be reached in the blood after continuous therapy regimens, and these results are therefore of practical interest. They expand our knowledge of the effects of AF on PMN cells, whereby reducing effects on intracellular ATP were observed with AF alone and stimulating effects in combination with LTB4. With low AF concentrations, the reduction of the ATP level is only a part of its action that seems to be independent of its effect on cell migration and chemotaxis.
Similar content being viewed by others
References
Forestier, J. 1935. Rheumatoid arthritis and its treatment by gold salts: Results of six years experiments.J. Clin. Lab. Clin. Med. 20:827–840.
Carette, S., A. Calin, J. P. McCafferty, andB. A. Wallin. 1989. The Auranofin Cooperating Group. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis.Arthritis Rheum. 32:158–165.
Ward, J. R., H. J. Williams, M. J. Egger, J. C. Reading, E. Boyce, M. Altz-Smith, C. O. Samuelson, Jr., R. F. Willkens, M. A. Solsky, S. P. Hayes, K. L. Blocka, A. Wein-Stein, R. F. Meenan, M. Guttadauria, S. B. Kaplan, andJ. Klippel. 1983. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial.Arthritis Rheum. 26:1303–1315.
Wenger, M. E., S. Alexander, J. Bland, andW. J. Blechman. 1983. Auranofin versus placebo in the treatment of rheumatoid arthritis.Am. J. Med. 75:123–127.
Elmgreen, J., I. Ahnfelt-Ronne, andO. H. Nielsen. 1989. Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway.Ann. Rheum. Dis. 48:134–138.
Hurst, N. P., L. Gorjatschko, W. H. Betts, P. D. Zalewski, andI. J. Forbes. 1989. Auranofin modulates human neutrophil Superoxide production and protein phosphorylation.Rheumatol Int. 8:245–250.
Pham Huy, D., M. Roch-Arveiller, O. Muntaner, andJ. P. Giroud. 1985. In vitro and in vivo effects of gold salts on chemotaxis and random migration of rat polymorphonuclear leucocytes.Agents Actions 16:363–368.
Partsch, G., C. Schwarzer, andR. Eberl. 1990. The effects of ibuprofen and diclofenac on the chemotaxis and adenosine triphosphate level of polymorphonuclear cells in vitro.J. Rheumatol. 17:583–588.
Partsch, G., andC. Schwarzer. 1991. Bioluminescence, an indirect method for the quantitative measurement of polymorphonuclear cell chemotaxis.J. Biolumin. Chemilumin. 6:159–167.
Boyden, S. V. 1962. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes.J. Exp. Med. 115:453–466.
Zigmond, S. H., andJ. G. Hirsch. 1973. Leukocyte locomotion and chemotaxis.J. Exp. Med. 137:387–410.
Elferink, J. G. R., andB. M. De Koster. 1993. Potentiation and inhibition of migration of human neutrophils by auranofin.Ann. Rheum. Dis. 52:595–598.
Betts, W. H., N. P. Hurst, G. A. Murphy, andL. G. Cleland. 1990. Auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase/LTA synthase activity of isolated human neutrophils.Biochem. Pharmacol. 39:1233–1237.
Mahoney, C. W., C. E. Hensey, andA. Azzi. 1989. Auranofin, gold thiomalate, and gold thioglucose inhibit protein kinase C.Biochem. Pharmacol. 19:3383–3386.
Parente, J. E., M. P. Walsh, P. R. Girard, J. F. Kuo, D. S. Ng, andK. Wong. 1989. Effects of gold coordination complexes on neutrophil function are mediated via inhibition of protein kinase C.Mol. Pharmacol. 35:26–33.
Hurst, N. P., L. Gorjatschko, W. H. Betts, P. D. Zalewski, andI. J. Forbes. 1989. Auranofin modulates human neutrophil Superoxide production and protein phosphorylation.Rheumatol. Int. 8:245–250.
Cronstein, B. N., L. Daguma, D. Nichols, A. J. Hutchison, andM. Williams. 1990. The adenosine/neurophil paradox resolved: Human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively.J. Clin. Invest. 85:1150–1157.
Rudkowski, R., J. B. Ziegler, G. G. Graham, andG. D. Champion. 1991. Auranofin inhibits the activation pathways of polymorphonuclear leukocytes at multiple sites.Biochem. Pharmacol. 41:1921–1929.
Rudkowski, R., G. G. Graham, G. D. Champion, andJ. B. Ziegler. 1990. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes-I.Biochem. Pharmacol. 39:1687–1695.
Marcolongo, R., M. Lalumera, A. Calabria, R. Gerli, C. Ales-Sandrini, andG. Robec-Chi. 1983. Effects of auranofin and other gold salts on polymorphonuclear neutrophil functions.In Auranofin. H. A. Capell, D. S. Cole, K. K. Manghani, and R. W. Morris, editors. Excerpta Medica, Amsterdam. 408–427.
Davidson, E. M., S. A. Rea, andM. J. H. Smith. 1983. Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis.Ann. Rheum. Dis. 42:677–679.
Mowat, A. G., andJ. Baum. 1971. Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis.J. Clin. Invest. 50:2541–2549.
Hanlon, S. M., G. S. Panayi, andR. Laurent. 1980. Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor.Ann. Rheum. Dis. 39:68–74.
Hafstroem, I., B. E. Seligmann, M. M. Friedman, andJ. I. Gallin. 1984. Auranofin affects early events in human polymorphonuclear neutrophil activation by receptor-mediated stimuli.J. Immunol. 132:2007–2014.
Sheikh, I. A., andA. P. Kaplan. 1987. Assessment of kininases in rheumatic diseases and the effect of therapeutic agents.Arthritis Rheum. 30:138–145.
Herlin, T., K. Fogh, N. O. Christiansen, andK. Kragballe. 1989. Effect of auranofin on eicosanoids and protein kinase C in human neutrophils.Agents Actions 28:121–129.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Partsch, G., Matucci-Cerinic, M. Auranofin and its combination with LTB4 influences ATP level and migration of human polymorphonuclear cells in vitro. Inflammation 19, 277–288 (1995). https://doi.org/10.1007/BF01534387
Issue Date:
DOI: https://doi.org/10.1007/BF01534387